Satellos Bioscience Inc.
About Satellos Bioscience Inc.
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $117.1M
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $117.1M
- Shares outstanding
- 19.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 18, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Trading 53% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Satellos Bioscience Inc..
Write a review
News about Satellos Bioscience Inc.
News & sentiment via Polygon.io
